GlobeNewswire

PHILADELPHIA, June 25, 2022 (GLOBE NEWSWIRE) -- Investor protection law firm Kaskela Law LLC announces that it is investigating SunPower Corp. (“SunPower” or the “Company”) (NASDAQ: SPWR) on behalf of the company’s current stockholders. On January 20, 2022, SunPower disclosed that it had “identified a cracking issue that developed over time in certain factory-installed connectors,” and that the Company “expects approximately $27 million of supplier-quality related charges in fourth ...

Primary Logo

PHILADELPHIA, June 25, 2022 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Convey Health Solutions Holdings, Inc. (“Convey Health”) (NYSE: CNVY) on behalf of the company’s current stockholders. On June 18, 2021, Convey Health completed its initial public offering (“IPO”) of common stock, selling over 11.6 million shares of stock to investors at a price of $14.00 per share. By May 2022, shares of Convey Health’s stock had declined in value to approximately ...

Primary Logo

PHILADELPHIA, June 25, 2022 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Hemisphere Media Group, Inc. (“Hemisphere”) (NASDAQ: HMTV) on behalf of the company’s shareholders. On May 9, 2022, Hemisphere announced that it had agreed to be acquired by its controlling stockholder, Gato Investments LP (“Gato”), a portfolio investment of Searchlight Capital Partners, L.P., at a price of $7.00 per share. Following the closing of the proposed transaction, ...

Primary Logo

NEW YORK, June 25, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Digital Turbine, Inc. (NASDAQ: APPS) between August 9, 2021 and May 17, 2022, both dates inclusive (the “Class Period”), of the important August 5, 2022 lead plaintiff deadline. SO WHAT: If you purchased Digital Turbine securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs ...

Primary Logo

NEW YORK, June 25, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Credit Suisse Group AG (NYSE: CS) between March 19, 2021 and March 25, 2022, inclusive (the “Class Period”), of the important June 28, 2022 lead plaintiff deadline. SO WHAT: If you purchased Credit Suisse securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a ...

Primary Logo

NEW YORK, June 25, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Axsome Therapeutics, Inc. (NASDAQ: AXSM) between December 30, 2019 and April 22, 2022, inclusive (the “Class Period”), of the important July 12, 2022 lead plaintiff deadline. SO WHAT: If you purchased Axsome securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a ...

Primary Logo

NEW YORK, June 25, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the common stock of Dentsply Sirona Inc. (NASDAQ: XRAY) between June 9, 2021 and May 9, 2022, both dates inclusive (the “Class Period”), of the important August 1, 2022 lead plaintiff deadline. SO WHAT: If you purchased Dentsply common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a ...

Primary Logo

Omicron-adapted monovalent candidate given as a fourth booster dose elicited a 13.5 and 19.6-fold increase in neutralizing geometric titers against Omicron BA.1 at 30 µg and 60 µg dose levels; bivalent vaccine candidate exhibited a 9.1 and 10.9-fold increase against Omicron Geometric mean ratios for Omicron neutralizing antibody response consistent with regulatory requirement of superiorityPreliminary laboratory studies demonstrate both Omicron-adapted candidates neutralize Omicron ...

Primary Logo

Late-breaking data from the double-blind portion of the noninvasive Phase 3 MAESTRO NAFLD-1 study show resmetirom to be safe and well-tolerated and to reduce liver fat, fibrosis measures on FibroScan and MRE, and liver enzymes, as well as multiple atherogenic lipidsIn NASH patients with well-compensated cirrhosis, resmetirom: was safe and well toleratedreduced liver fat, LDL-C, and other atherogenic lipidsreduced noninvasive measures of liver fibrosis and liver enzymesreduced liver ...

Primary Logo

– Results from ongoing trials of VIR-2218 and VIR-3434 presented at the International Liver Congress™ (ILC) 2022 demonstrate durable reductions in hepatitis B surface antigen with no safety signals – – Company expects to dose first patient in Part B of the Phase 2 MARCH trial by the end of June – SAN FRANCISCO, June 25, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from its robust hepatitis B virus (HBV) clinical trial program, including ...

Primary Logo

MAHE, SEYCHELLES, June 25, 2022 (GLOBE NEWSWIRE) -- Nakamoto Games ($NAKA), the token powering the industry's fastest-growing play-to-earn gaming ecosystem, is entering a new growth phase with exciting prospects. On Monday, June 27th, 2022, Nakamoto Games will release the last $NAKA token allocation batch to private sale investors. The latest release comes ahead of schedule and follows a favorable turnaround in crypto market conditions. It also marks the beginning of a new phase ...

AB-729, our RNAi therapeutic, provided robust and comparable HBsAg declines in both HBeAg+ and HBeAg- patients 50% (16 out of 32) of patients maintained HBsAg levels below 100 IU/mL 24 weeks after their last AB-729 dose In the first five patients who discontinued both AB-729 and NA therapy after meeting stopping criteria, there has been no evidence of virologic or clinical relapse in 8-24 weeks of follow-up Preliminary data to date have shown that AB-729 remains generally safe and ...

Primary Logo

PRESS RELEASE Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™ IMC-I109V, T cell receptor bispecific, targets an envelope antigen Single Ascending Dose portion of Phase 1 study to evaluate safety, antiviral activity, and pharmacokinetics In the initial cohort, HBsAg declines and ALT elevations indicated that a single, very low dose of IMC-I109V elicited on-target activity, ...

Primary Logo

NEW YORK, June 24, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of F-star Therapeutics, Inc. (FSTX) (“F-star”) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by invoX Pharma (“invoX”). Click here to learn more and participate in the action. On June 23, 2022, F-star announced that ...

Primary Logo

NEW YORK, June 24, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of RADA Electronic Industries Ltd. (“RADA”) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Leonardo DRS (“Leonardo DRS”). Click here to learn more and participate in the action. On June 21, 2022, RADA announced ...

Primary Logo

NEW YORK, June 24, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Radius Health, Inc. ("Radius") breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by an entity jointly owned by Gurnet Point Capital & Patient Square Capital ("Gurnet Point and Patient Square"). Click here to learn ...

Primary Logo

NEW YORK, June 24, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of U.S. Well Services, Inc. (“USWS”) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by ProFrac Holding Corp. (NASDAQ: PFHC) ("ProFrac"). Click here to learn more and participate in the action. On June 21, 2022, USWS ...

Primary Logo

NEW YORK, June 24, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Natera, Inc. (NASDAQ: NTRA) between February 26, 2020 and April 19, 2022, inclusive (the “Class Period”), of the important June 27, 2022 lead plaintiff deadline. SO WHAT: If you purchased Natera securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee ...

Primary Logo

NEW YORK, June 24, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Enservco Corporation (NYSE American: ENSV) between May 13, 2021 and April 18, 2022, both dates inclusive (the “Class Period”), of the important July 19, 2022 lead plaintiff deadline. SO WHAT: If you purchased Enservco securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs ...

Primary Logo

NEW YORK, June 24, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Okta, Inc. (NASDAQ: OKTA) between March 5, 2021 and March 22, 2022, both dates inclusive (the “Class Period”), of the important July 19, 2022 lead plaintiff deadline. SO WHAT: If you purchased Okta securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee ...

Primary Logo